Albireo Pharma Inc ROCE
What is the ROCE of Albireo Pharma Inc?
The ROCE of Albireo Pharma Inc is -43.59%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with roce similar to Albireo Pharma Inc
- Apyx Medical has ROCE of -43.78%
- HUTCHMED (China) has ROCE of -43.71%
- Goodrich Petroleum has ROCE of -43.68%
- Stoke Therapeutics has ROCE of -43.66%
- Adverum Biotechnologies Inc has ROCE of -43.65%
- Ultragenyx Pharmaceutical has ROCE of -43.61%
- Albireo Pharma Inc has ROCE of -43.59%
- e-Play Digital has ROCE of -43.44%
- e-Therapeutics Plc has ROCE of -43.43%
- Western Metallica Resources Cor has ROCE of -43.42%
- Petros Pharmaceuticals has ROCE of -43.21%
- European Assets Trust Plc has ROCE of -43.17%
- StartEngine Crowdfunding has ROCE of -43.17%